{"schema_version":"secwatch.filing_event.v1","accession":"0001162194-23-000055","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.258489+00:00","generated_at":"2026-06-12T00:45:56.953255+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Standard BioTools Q2 revenue up 47% to $27.7M; gross margins surge","bullets":["Revenue $27.7M (+47% YoY); GAAP gross margin 49.2% vs 23.6% YoY.","Non-GAAP gross margin 60.9% vs 40.2%; operating loss improved to ($17.4M) from ($38.6M).","Non-GAAP operating expenses down 25% to $25.2M; net loss ($17.0M) vs ($63.5M).","Non-GAAP adjusted EBITDA loss ($8.4M) vs ($26.2M); operating cash use down >70% to $8.5M.","Cash and equivalents $143.1M; launched Hyperion XTi Imaging System."],"urls":{"canonical":"https://secwatch.observer/filing/0001162194-23-000055","json":"https://secwatch.observer/filing/0001162194-23-000055.json","markdown":"https://secwatch.observer/filing/0001162194-23-000055.md","text":"https://secwatch.observer/filing/0001162194-23-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000116219423000055/0001162194-23-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000116219423000055/lab-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T00:45:56.953255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8360422248fbad30eae69cdb72044f6611b951bc","claim":"STANDARD BIOTOOLS INC. reported quarter ended June 30, 2023 results: revenue $27.7, net income ($17.0).","evidence_excerpt":"Selected Financial Results (Numbers in millions, except percentages) Quarter Ended June 30, 2023 Quarter Ended June 30, 2022 Revenue $27.7 $18.8 (a) Gross margin 49.2% 23.6% Non-GAAP gross margin 60.9% 40.2% Operating expenses $31.1 $43.0 Non-GAAP operating expenses $25.2 $33.8 Operating loss ($17.4) ($38.6) Net loss ($17.0) ($63.5)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219423000055/0001162194-23-000055-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Revenue","value":"$27.7"},{"label":"Net income","value":"($17.0)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}